dc.contributor.author |
Marshall, KM |
en |
dc.contributor.author |
Holden, JA |
en |
dc.contributor.author |
Koller, A |
en |
dc.contributor.author |
Kashman, Y |
en |
dc.contributor.author |
Copp, Brent |
en |
dc.contributor.author |
Barrows, LR |
en |
dc.date.accessioned |
2017-10-30T01:36:58Z |
en |
dc.date.available |
2004-07-04 |
en |
dc.date.issued |
2004-10 |
en |
dc.identifier.citation |
Anti-Cancer Drugs, 15(9):907-913 01 Oct 2004 |
en |
dc.identifier.issn |
0959-4973 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/36285 |
en |
dc.description.abstract |
Pyridoacridines are marine natural products that contain planar structures. Almost all are cytotoxic and capable of DNA intercalation. Several pyridoacridines have demonstrated anti-cancer activity, being able to generate reactive oxygen species or to inhibit topoisomerase (Topo) II. Synthetic pyridoacridines were characterized and compared to other pyridoacridines as well as the Topo-inhibiting drugs (etoposide, 9-aminocamptothecin and wakayin) in a series of in vitro enzyme systems. We found AK37 was able to stabilize a DNA–Topo I cleavable complex, but not a DNA–Topo II cleavable complex. To our knowledge, this is the first report of a DNA–Topo I cleavable complex stabilizing pyridoacridine. Structure comparison studies demonstrated that this activity was lost when an extra ‘F’ ring was added, but activity was not affected when the ‘D’ ring was removed. AK37 inhibited the catalytic activity of both human Topo I and II. |
en |
dc.description.uri |
https://www.ncbi.nlm.nih.gov/pubmed/15457132 |
en |
dc.language |
English |
en |
dc.publisher |
Lippincott, Williams & Wilkins |
en |
dc.relation.ispartofseries |
Anti-Cancer Drugs |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://sherpa.ac.uk/romeo/issn/0959-4973/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
AK37: the first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1097/00001813-200410000-00012 |
en |
pubs.issue |
9 |
en |
pubs.begin-page |
907 |
en |
pubs.volume |
15 |
en |
dc.rights.holder |
Copyright: Lippincott, Williams & Wilkins |
en |
dc.identifier.pmid |
15457132 |
en |
pubs.author-url |
http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2004&issue=10000&article=00012&type=abstract |
en |
pubs.end-page |
913 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
7649 |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Chemistry |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
dc.identifier.eissn |
1473-5741 |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
15457132 |
en |